A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer\'s disease (AD).
Epistemonikos ID: f10d7a89e7bddd290085321a20065d7424ae7235
First added on: Oct 01, 2024